pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,047 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints579BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps22
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • STAT+: The end for GSK’s chronic cough treatment
    Sonothera's ultrasound gene therapy delivery, a new Alzheimer's drug controversy, and more biotech news from The Readout
    STAT · 7d ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    STAT · 7d ago↗ source
  • STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and more
    The number of active medication shortages in the U.S. rose to 227 in the second quarter of 2026
    STAT · 7d ago↗ source
← prev
page 7 of 42
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail
    Camlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said.
    BioSpace · 7d ago↗ source
  • BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
    Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperw…
    Fierce Biotech · 7d ago↗ source
  • Who can access testosterone hormone medication in the U.S.?
    Wildfire smoke health hazards, a new idea for treating Duchenne, and more health news from Morning Rounds
    STAT · 7d ago↗ source
  • Insmed moves closer to $6B opportunity as PAH drug shows long-term durability
    Insmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements thro…
    BioSpace · 7d ago↗ source
  • FDA disavows Makary, Prasad’s papers as lawmaker blasts ‘shoot-from-the-hip’ policymaking
    Journal publications that suggested changes in FDA guidelines do not “communicate FDA policy or interpretation of a regulatory issue,” acting director Kyle Diamantas wrote in a letter to House Ener…
    BioSpace · 7d ago↗ source
  • Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Mirador
    Jasper Therapeutics is being reborn via a merger with Nasdaq-listed immune-mediated disease biotech Kira Pharmaceuticals.
    Fierce Biotech · 7d ago↗ source
  • 5 emerging biotech hubs
    Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of cities. But which emerging hubs could become dominant forces in biotech in the decades ahead?
    Fierce Biotech · 7d ago↗ source
  • STAT+: Can ultrasound unlock the power of gene therapy? A startup makes big claims
    Sonothera is developing a new way to deliver genes into cells that, if borne out, could have a big impact on muscular dystrophy and other diseases.
    STAT · 7d ago↗ source
  • Opinion: MAHA is rewriting the vocabulary of American mental health care
    “‘Deprescribing’ elevated into a movement, and a cultural default, is a clinical hazard,” writes Sunny Patel.
    STAT · 7d ago↗ source
  • STAT+: MDCalc is scoring the clinical calculators used by millions of doctors
    MDCalc is launching a quality-rating system for the more than 800 clinical calculators used to assess disease risk, transplant eligibility, and more.
    STAT · 7d ago↗ source
  • Why affirming trans identities can be critical for suicide prevention counseling
    Advocates worry that excluding trans youth in some way from LGBTQ+ counseling services provided through the 988 crisis line could be harmful.
    STAT · 7d ago↗ source
  • Abbott Q2 led by strong device, diagnostic sales as it boosts profit forecast
    Abbott turned in a stronger-than-expected second quarter, allaying market concerns that subsidy cuts to the Affordable Care Act by the Trump administration would hurt medtech firms.
    Fierce Biotech · 7d ago↗ source
  • GSK axes key cough drug candidate after phase 3 data end blockbuster hopes
    GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the dru…
    Fierce Biotech · 7d ago↗ source
  • Dimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M deal
    Dimerix has bought an acute kidney injury drug from Mission Therapeutics, paying $5 million upfront and committing up to $287 million in milestones for the phase 2-ready asset.
    Fierce Biotech · 7d ago↗ source
  • Biotronik Neuro snaps up spinal cord stimulation portfolio from Soin Neuroscience for next-gen pain project
    Biotronik Neuro has acquired a portfolio of spinal cord stimulation patents from the Ohio-based medical device company Soin Neuroscience as the pair look to create “a next-generation spinal cord st…
    Fierce Biotech · 7d ago↗ source
  • STAT+: Fresh turmoil roils American Diabetes Association following controversy at conference
    Turmoil at the ADA has taken a fresh turn, with leaders blocking editors at its flagship journal from publishing pieces detailing a controversy at the group’s annual meeting.
    STAT · 8d ago↗ source
  • Predicting biotech clinical trials and a new Alzheimer’s drug controversy
    This week on "The Readout LOUD" podcast: a new Alzheimer's drug controversy and prediction markets for clinical trials and FDA drug reviews. Listen now.
    STAT · 8d ago↗ source
  • STAT+: GOP blocks effort to end Medicare test of AI prior authorization
    The Trump administration is testing the use of AI in Medicare to approve some medical services.
    STAT · 8d ago↗ source
  • STAT+: Despite earnings celebration, UnitedHealth signals more financial pain for employers
    Insurance giant UnitedHealth signals the cost of providing workers with health insurance will climb even higher.
    STAT · 8d ago↗ source
  • Pete Hegseth’s announcement of annual testosterone screenings for service members divides medical experts
    Medical experts are divided on Defense Secretary Pete Hegseth’s announcement that U.S. service members will undergo annual testosterone screenings.
    STAT · 8d ago↗ source
  • WHO: Uganda is silent on updates following disclosure of Marburg outbreak
    The government of Uganda has gone quiet on an outbreak of the deadly Marburg virus that it reported late last month, the WHO acknowledged.
    STAT · 8d ago↗ source
  • ‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D wins
    A string of recent wins on the frontiers of novel drug development could mean that a homegrown innovation industry is within reach.
    Fierce Biotech · 8d ago↗ source